Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Palorini, Federica; Rancati, Tiziana; Cozzarini, Cesare; Improta, Ilaria; Carillo, Viviana; Avuzzi, Barbara; Casanova Borca, Valeria; Botti, Andrea; Degli Esposti, Claudio; Franco, Pierfrancesco; Garibaldi, Elisabetta; Girelli, Giuseppe; Iotti, Cinzia; Maggio, Angelo; Palombarini, Marcella; Pierelli, Alessio; Pignoli, Emanuele; Vavassori, Vittorio; Valdagni, Riccardo; Fiorino, Claudio
• Is Part Of: Radiotherapy and oncology. Volume 118:Issue 1(2016:Jan.)
• Page Start: 92
• Page End: 98
• Publication Date: 2016-01
• Subjects: Radiotherapy -- Prostate cancer -- Urinary toxicity -- Dose–volume effects; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2015.11.036
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Purpose/objective: Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods: DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2–2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose–surface histograms (DSHw ) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ⩾ 10 and ΔIPSS ⩾ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results: Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ⩾ 10 and ΔIPSS ⩾ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup ( n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ⩾ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ⩾ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion: Current study shows a dose–surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.